^
Association details:
| Biomarker: | SRSF2 mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Published date:
02/22/2021
Excerpt:
...a statistically significant survival advantage for treatment with lenalidomide in 58 patients with SRSF2-mutated AML (57% vs 33% EFS at 4 years; HR, 0.47; 95% CI, 0.23-0.96; P = .04; supplemental Figure 2)....The advantage of lenalidomide treatment in the SRSF2-mutated subset was also apparent regarding OS (68% vs 43% at 4 years; HR, 0.42; 95% CI, 0.19-0.94; P = .03).
DOI:
10.1182/bloodadvances.2020003855
